RespireRx Pharmaceuticals Inc.
RSPI
$0.0021
$0.0011110.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.95% | -26.17% | -44.61% | -38.09% | -40.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.70% | -28.98% | -43.06% | -38.28% | -35.69% |
| Operating Income | 24.70% | 28.98% | 43.06% | 38.28% | 35.69% |
| Income Before Tax | 30.56% | 33.64% | 46.98% | 33.13% | 24.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.56% | 33.64% | 46.98% | 33.13% | 24.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.56% | 33.64% | 46.98% | 33.13% | 24.59% |
| EBIT | 24.70% | 28.98% | 43.06% | 38.28% | 35.69% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 63.42% | 27.62% | 20.05% | 9.87% | 46.48% |
| Normalized Basic EPS | 50.99% | 53.01% | 58.02% | 44.89% | 46.45% |
| EPS Diluted | 63.42% | 27.62% | 20.05% | 9.87% | 46.48% |
| Normalized Diluted EPS | 50.99% | 53.01% | 58.02% | 44.89% | 46.45% |
| Average Basic Shares Outstanding | 63.39% | 37.84% | 27.39% | 23.47% | 31.99% |
| Average Diluted Shares Outstanding | 63.39% | 37.84% | 27.39% | 23.47% | 31.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |